In clinical tissues, miR‐500a‐3p is significantly enriched in HCC and cirrhosis tissues, and co‐expression of the immune marker CD4 or PD‐L1 significantly correlates with low survival rates in patients. Here, CD4 is linked to hepatocellular carcinoma.